There are 42 FIRs against Yeddyurappa; Let him come out of them: Siddaramaiah

Bengaluru, Jul 22: Karnataka's Covid-19 task force on Tuesday decided that the state government will regulate the supply of Remdesivir, the drug used in the treatment of coronavirus infected patients, to private hospitals to check black marketing and hoarding.

"Remdesivir which is currently available in the government hospitals will be supplied to private hospitals through the government.

This will help curb black marketing of this drug," Medical Education Minister K Sudhakar's office said in a release.

Along with Sudhakar, other task force members, including Health Minister Sriramulu, Deputy Chief Minister C N Ashwath Narayan and Chief Secretary T M Vijay Bhaskar attended the meeting. However, Home Minister Basavaraj Bommai was not part of it as he was out of Bengaluru.

At the meeting, the government has also fixed the rate for Covid-19 tests in private labs- Rs 2,000 for government referred cases and 3,000 for self-reporting cases.

It was also decided to purchase 4 lakh antigen test kits and 5 lakh swab test kits to ramp up testing, the release said, adding that approvals have also been given for additional drugs for the treatment of Covid-19 patients.

The decisions also included increasing monthly salary for Ayush doctors to 48,000, MBBS doctors to 80,000 and nurses to get 30,000 for next 6 months.

The task force also made it clear that private hospitals have to reserve 50 percent beds for the government for Covid-19 treatment. The remaining 50 percent can be used by the private hospitals for Covid-19 and non-Covid-19 treatment.

Private hospitals provide treatment under Ayushman Bharat scheme (ABARK) for Covid-19 patients.

Those cases in which treatment does not cover under the scheme can be charged as per the user charges, the release said.

A committee will be formed to supervise and recommend the purchase of equipment and medicines for Covid-19 treatment, which will be headed by ACS, ITBT Department.

Approval has been given for the procurement of N-95 masks and lakh PPE kits for the safety of healthcare workers. The decision also has been taken to connect oxygen pipeline to 4,736 beds in 17 government medical colleges, which will enable high flow oxygen for these beds besides being beneficial for future use as well.

According to the release, 16 RTPCR and 15 Automated RNA extraction units will be established to ramp up testing and this will help achieve the target of 50,000 tests per day. "On the whole approvals given for purchase of equipment and upgradation of existing facilities at government hospitals is estimated to be about Rs 500 Crore," it added.

New Delhi, Jun 11: The Department of Pharmaceuticals has given its nod for lifting of ban on the export of hydroxychloroquine, Union Minister D V Sadananda Gowda said on Wednesday.

India had banned export of hydroxychloroquine on March 25, with some exceptions, amid views in some quarters that the drug could be used to fight COVID-19. On April 4, it completely banned the exports without any exception.

"Department of Pharmaceuticals has approved the lifting of ban on export of Hydroxychloroquine API as well as formulations. Manufacturers except SEZ/EOU Units have to supply 20 per cent production in the domestic market," the minister of chemicals and fertilisers said in a tweet.

The Directorate General of Foreign Trade (DGFT) has been asked to issue formal notification in this regard, he added.

In another tweet, Gowda said he held discussions with representatives of pharma companies along with some of his ministerial colleagues on the challenges being faced by the industry and on the roadmap to boost exports.

"Had detailed discussion with representatives of pharma companies & association, stakeholder Ministries along with Hon Ministers @piyushGoyal  ji, @HardeepSPuri  ji, & @MansukhMandviya  ji on entire gamut of challenges faced by the industry as well as strategies to boost pharma export," Gowda tweeted.

India exported hydroxychloroquine API (active pharmaceutical ingredient) worth USD 1.22 billion in April-January 2019-20.

During the same period, exports of formulations made from hydroxychloroquine was at USD 5.50 billion.

Mangaluru, May 9: A team of doctors at Mangaluru's Mangala Hospital has developed a 'bubble helmet' that will provide an alternative to patients who need an oxygen mask.

The team was led by Dr Ganapathi, medical director of Mangala Hospital and Mangala Kidney Foundation in the city.

The bubble helmet, which has a special collar attached to it, helps the patients with breathing issues, and to avoid using ventilator facility.

Dr Ganapathi said, "When a patient needs intubation we will be providing them oxygen bubble helmets and we will first give it a trial before we intubate a patient."

"I have converted an ordinary snorkelling mask into a ventilator assist device, this mask can be used as a personal protection device by connecting it to a bacterial viral filter," he added.

Dr Ganapathi said that the connector has been made available in India and a snorkelling mask can be easily converted into a ventilator assist device. And it will make the management of coronavirus patients easy.